Paragon Care (ASX:PGC) FY26 Results to Test Healthcare Roll-Up Strategy

Aditi Sarkar

17 August 2026 12:06 PM AEST

Paragon Care (ASX:PGC) FY26 Results to Test Healthcare Roll-Up Strategy

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Paragon Care (ASX:PGC) will release FY26 full-year results on 26 August 2026 following a year impacted by a significant bad-debt provision.
First-half FY26 Revenue increased 2.9 per cent to $1.9 billion, while underlying EBITDA rose 3.1 per cent to $49.0 million.
FY26 guidance targets revenue of $3.6 billion to $3.7 billion and underlying EBITDA of $97 million to $107 million.
Contract Logistics and Medical Technology divisions recorded growth during H1 FY26, partially offsetting pressure in Wholesale.

Paragon Care (ASX:PGC) enters its FY26 results with investors focused on whether its healthcare distribution transformation is beginning to deliver consistent operating performance. The company has expanded through acquisitions across medical supplies, pharmaceuticals and logistics, creating a larger healthcare platform across Australia, New Zealand and Asia. However, a significant provision against an impaired receivable affected statutory results and weighed on market confidence. The 26 August full-year release will provide a clearer view of integration progress, Earnings quality and the company's path forward.

Latest Development

On 7 August 2026, Paragon Care confirmed it would release its FY26 full-year results on Wednesday 26 August, followed by an investor conference call and webcast hosted by chief executive and managing director Carmen Riley and chief financial officer Brendon Pentland.

The results will provide the first full-year assessment following the company's substantial restructuring and integration activity. The period included a major provision related to the Infinity Group receivable, which affected statutory earnings and became a key focus for investors.

Management has positioned FY26 as a transition year, with the results expected to provide further detail on operational performance, integration milestones and potential recovery from the impaired receivable.

What the Numbers Show

The first-half FY26 results highlighted the difference between underlying operations and statutory outcomes. Revenue increased 2.9 per cent to $1.9 billion, while underlying EBITDA rose 3.1 per cent to $49.0 million. Underlying net profit after tax increased marginally to $13.3 million.

Statutory results were affected by a $46.4 million provision, net of recoverable GST, related to the Infinity Group receivable, alongside a further $1.2 million carried from FY25. Statutory EBITDA declined to a $0.4 million loss.

Divisional performance was mixed. Wholesale revenue declined 2.6 per cent to $1.5 billion, Medical Technology increased 15.3 per cent to $155.6 million, Contract Logistics increased 47.1 per cent to $235.5 million, and Clinical Manufacturing declined 5.2 per cent to $13.8 million.

Why It Matters

The key issue for Paragon Care is whether the underlying healthcare platform can generate consistent earnings after years of acquisition-led expansion. Management is asking investors to separate the one-off impact of the Infinity provision from the operating performance of the broader group.

FY26 guidance provides the main benchmark, with revenue expected at $3.6 billion to $3.7 billion and underlying EBITDA targeted at $97 million to $107 million. Achieving these targets would demonstrate that the acquired businesses are generating sufficient scale and that integration efforts are progressing.

The market remains cautious, reflected in the company's lower valuation, meaning operational delivery will be important in rebuilding confidence.

Growth Catalysts

The main strategic catalyst is completion of the company's "3-2-1" integration strategy, which combines the legacy Paragon Care Business with CH2 (Clifford Hallam Healthcare) and Oborne. Successful integration could improve operational efficiency and allow the company to capture expected synergies.

The faster-growing Medical Technology and Contract Logistics divisions provide potential earnings Diversification away from the lower-margin Wholesale segment. Contract Logistics growth in particular provides exposure to healthcare supply-chain services.

The Infinity receivable recovery could also support balance-sheet flexibility. The company expects a partial cash recovery of approximately $11.7 million to $15.8 million, in addition to a $3.4 million GST refund already received.

Risks Investors Should Watch

The largest risk remains balance-sheet pressure and execution following years of Acquisition activity. Net Debt is expected to finish FY26 at around two times underlying EBITDA, limiting flexibility if further challenges emerge.

The Infinity receivable issue highlights Credit exposure within a distribution business operating on relatively thin margins, where a single customer event can materially affect statutory earnings. Integration risk also remains significant, with multiple businesses requiring operational alignment.

Wholesale remains the largest division but has experienced revenue pressure, while negative free Operating Cash Flow in FY25 means deleveraging still requires further evidence through improved cash generation.

What Happens Next

The 26 August FY26 result will provide several key indicators. Investors will focus on whether underlying EBITDA lands within the $97 million to $107 million guidance range, whether net debt remains near the targeted level and whether any Dividend reinstatement is considered.

The market will also assess progress on the 3-2-1 integration strategy and whether management considers the restructuring phase complete. Commentary around Wholesale performance, Contract Logistics growth and the Infinity recovery outcome will influence expectations for FY27.

Conclusion

Paragon Care (ASX:PGC) approaches FY26 results with a business that has expanded significantly but still needs to prove the benefits of its healthcare roll-up strategy. The company has built a large healthcare distribution platform, with growth from Medical Technology and Contract Logistics providing support, but the Infinity provision highlighted the risks of scale and integration. The upcoming results will determine whether underlying earnings strength is sufficient to offset previous challenges and whether the company can transition from restructuring toward sustainable growth.

FAQs

Q: When will Paragon Care release FY26 results?

A: Paragon Care will release its FY26 full-year results on 26 August 2026.

Q: What is Paragon Care's FY26 EBITDA guidance?

A: Underlying EBITDA guidance is $97 million to $107 million.

Q: What affected Paragon Care's statutory earnings?

A: A $46.4 million provision related to the Infinity Group receivable affected statutory results.

Q: Which Paragon Care divisions are growing?

A: Medical Technology and Contract Logistics recorded growth during H1 FY26.

Q: What is the key focus for FY26 results?

A: Investors will focus on integration progress, earnings delivery, debt levels and potential Infinity recovery.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.